Have you been using compounded Tirzepatide for weight loss or blood sugar management? Learn about the important announcement that it will no longer be available after March 2025. The FDA has officially removed Tirzepatide from the drug shortage list. 

What does it mean for you? The removal of Tirzepatide from FDA’s drug shortage list means that compounding pharmacies must stop producing it, a decision aimed to ensure medication safety and regulatory compliance. 

What Now?

If you’ve been using compounded Tirzepatide, it’s time to explore alternatives—many people are switching to Semaglutide or the oral version of Tirzepatide. Talk to your healthcare provider to find the best option for you!

In this blog, we’ll dive into why this change is happening, how Semaglutide can help you stay on track with your health goals, and the best way to make a smooth transition. Keep reading to learn everything you need to know!

Why Is Compounded Tirzepatide Being Discontinued?

Compounded Tirzepatide gained popularity due to its effectiveness in weight management and blood sugar control. Now that the FDA has declared the shortage of brand-name Tirzepatide (Mounjaro, Zepbound) officially over, compounding pharmacies can no longer legally produce it. Check out the official FDA announcement here and learn more about your next steps!

Why Semaglutide is a Powerful Alternative to Tirzepatide?

If you’re looking for a replacement for compounded Tirzepatide, Semaglutide might be your best bet. Like Tirzepatide, Semaglutide is a GLP-1 receptor agonist, meaning it helps regulate appetite, insulin secretion, and blood sugar levels. Extensive research has shown that it is highly effective for weight loss and metabolic health. Here’s why it’s a great alternative:

• Proven for Weight Loss
  Research shows that patients taking Semaglutide for weight management can lose a significant percentage of their body weight—especially when combined with a healthy lifestyle. A landmark study published in The New England Journal of Medicine found that participants on Semaglutide lost up to 15% of their body weight over 68 weeks.
• Better Blood Sugar Control
  Just like Tirzepatide, Semaglutide improves insulin sensitivity, lowers blood sugar levels, and reduces the risk of type 2 diabetes complications. Research from the American Diabetes Association confirms its effectiveness in glycemic control. Check out the ADA findings.
• Reduces Appetite & Cravings
  Semaglutide works directly on the brain’s hunger centers, helping you feel full longer and reducing food cravings—making it easier to stick to your health goals.
• FDA-Approved & Backed by Science
  Unlike compounded Tirzepatide, Semaglutide is fully FDA-approved for both weight loss (Wegovy) and diabetes management (Ozempic). That means it meets strict safety and quality standards. 
• More Accessible Options
  The good news? Semaglutide is widely available in various forms:
  • Injectable versions (prescription-based)
  • Compounded oral Semaglutide tablets
  • Compounded oral Semaglutide drops

If you’re making the switch, talk to your healthcare provider about the best option for you. Looking for where to buy? You can explore high-quality compounded Semaglutide options at MyProfusions for a seamless transition.

Switching doesn’t have to be stressful—Semaglutide offers a proven, effective, and accessible alternative! 

How to Transition from Tirzepatide to Semaglutide

If you’ve been using Tirzepatide and now need to switch to Semaglutide, it’s important to do so in a way that keeps your progress on track while minimizing any side effects. Here’s how you can make the transition as smooth as possible:

1. Consult Your Healthcare Provider – Before making any changes to your medication, talk to your doctor. They’ll help you determine the right dosage and timing to ensure a safe transition. If you need guidance, you can consult a provider online at MyProfusions.
2. Adjust to a New Dosing Schedule – Tirzepatide and Semaglutide have different dosing regimens. For example, Tirzepatide often starts at 2.5 mg weekly and increases gradually, whereas Semaglutide typically begins at 0.25 mg weekly before escalating. Working with your doctor will help ensure a smooth dosage adjustment that avoids unnecessary side effects like nausea or digestive issues.
3. Monitor Your Body’s Response – Keep an eye on key factors like weight, appetite, and blood sugar levels. Some people notice a slight difference in how the two medications affect them, so tracking your progress will help you and your doctor make any necessary tweaks.
4. Stick to a Healthy Lifestyle – Medication works best when combined with good nutrition and regular physical activity. Whether you’re taking Semaglutide for weight loss or blood sugar control, maintaining a balanced diet and staying active will improve your results.

Make the Switch Today

With compounded Tirzepatide being phased out, now is the perfect time to switch to a reliable, research-backed alternative. Semaglutide offers clinically proven benefits for weight loss and blood sugar management—and it’s FDA-approved for these uses.

How can we help? Consult our expert healthcare providers to understand your options. Explore our products at MyProfusions and take charge of your health today. Whether you need compounded Semaglutide prescribed online, oral Semaglutide prescribed online, or the most affordable weight-loss medication options, we provide trusted, science-backed solutions tailored to your needs.

References

• Kahn, S. E., Deanfield, J. E., Jeppesen, O. K., Emerson, S. S., Boesgaard, T. W., Colhoun, H. M., Kushner, R. F., Lingvay, I., Burguera, B., Gajos, G., Horn, D. B., Hramiak, I. M., Jastreboff, A. M., Kokkinos, A., Maeng, M., Matos, A. L. S. A., Tinahones, F. J., Lincoff, A. M., Ryan, D. H., & SELECT Trial Investigators (2024). Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes care, 47(8), 1350–1359. https://doi.org/10.2337/dc24-0491
• Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. (2021). Effects of once-weekly semaglutide on appetite, energy intake, and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 23(3), 765-776. https://doi.org/10.1111/dom.14206
• FDA. (n.d.). How to buy medicines safely from an online pharmacy. U.S. Food and Drug Administration. Retrieved March 9, 2025, from https://www.fda.gov/consumers/consumer-updates/how-buy-medicines-safely-online-pharmacy
• FDA. (n.d.). Drugs. U.S. Food and Drug Administration. Retrieved March 9, 2025, from https://www.fda.gov/drugs
• FDA. (2024). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I,& Kushner, R. F. (2022). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 387(2), 211-224. https://doi.org/10.1056/NEJMoa2206038